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Introduction
T-VEC, an intralesionally-delivered oncolytic immu-
notherapy, is a herpes simplex virus-1 engineered to
selectively replicate in tumors and stimulate an anti-
tumor immune response through expression of GM-
CSF. T-VEC has the ability to lyse various cancer cell
types in vitro[1]. A Phase III study of T-VEC injected
into skin, subcutaneous, or lymph node tumors versus
subcutaneous GM-CSF in advanced melanoma demon-
strated improved durable response rate for T-VEC, with
regression of both injected and uninjected lesions[2]. To
further explore if different types of cancers and locations
might be treatable with T-VEC, this Phase I study evalu-
ates whether primary and metastatic liver tumors may
be safely and effectively injected with T-VEC.
Methods
Approximately 100 patients will be enrolled. Primary
objective: evaluate maximum tolerated dose (MTD) of
intrahepatic injection of T-VEC by patient incidence of
dose-limiting toxicities (DLTs). Key secondary objectives:
overall safety, efficacy, and biodistribution of T-VEC. Key
eligibility criteria: breast, colorectal, gastroesophageal,
kidney, lung cancer or melanoma with liver metastases
(non-HCC) or hepatocellular carcinoma (HCC); measur-
able liver tumors suitable for injection; ECOG perfor-
mance status 0-1; life expectancy ≥5 months; ≥1 prior
standard systemic anticancer therapy (non-HCC); Child-
Pugh A-B7; no detectable hepatitis B/C viral load; not a
candidate for surgery or locoregional therapy of liver
tumors with curative intent or planned systemic anticancer
therapy; tumor in < 1/3 of the liver; no macroscopic intra-
vascular invasion. The study consists of two parts. Part 1:
3+3 dose escalation of 3 sequential dose cohorts each
administering T-VEC in increasing concentrations (107 or
108 PFU/mL) and volumes (up to 4 or 8 mL). MTD for
HCC is determined separately from non-HCC tumor types;
HCC cohorts will not proceed until safety at respective dose
levels are determined in non-HCC. Six T-VEC doses
injected under ultrasound or computed tomography gui-
dance q21 (±3) days are planned, with an investigator
option to continue for up to 6 additional doses. The first
dose of T-VEC in all dose cohorts is given at 106 PFU/mL.
Part 2: 7 expansion cohorts for each cancer type with
10 patients each administered the MTD of T-VEC
determined from Part 1.
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